Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
OMO-103 by Peptomyc for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
OMO-103 is under clinical development by Peptomyc and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Data Insights
OMO-103 by Peptomyc for Osteosarcoma: Likelihood of Approval
OMO-103 is under clinical development by Peptomyc and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs...